Clover Health Investments reported Q2 GAAP earnings of $0.05 per share, exceeding estimates by $0.02, and raised full-year guidance.
Clover Health Investments (CLOV) shares surged over 20% after the Medicare Advantage insurer reported second-quarter GAAP earnings of $0.05 per share, surpassing analyst estimates by $0.02. The company also raised its full-year financial guidance across all major metrics.
Analysts had anticipated weaker results, with consensus estimates set lower. The earnings beat and improved outlook reflect stronger-than-expected performance in the quarter.
The stock’s sharp rise follows the announcement, signaling investor confidence in the revised guidance and operational momentum.